REG - Goodwin PLC - Product Innovation

GoodwinAnnouncement

02/04/2019 09:30

RNS Number : 8210U
Goodwin PLC
02 April 2019
 


Goodwin PLC ("Goodwin", or the "Group")
Product Innovation
World's First Silica Free Jewellery Investment Casting  Powder
Goodwin PLC is pleased to announce that its subsidiary Goodwin Refractory Services Limited, the technical core of the Group's seven investment casting powder manufacturing companies around the world, has finally developed a silica free investment casting powder for which it has applied for a patent to protect its technology.
This new investment casting powder can be used by jewellery manufacturers to cast Gold, Silver and Brass jewellery castings without them having to change any of their existing equipment, processes or infrastructure. This breakthrough is the conclusion of over six years of research and development work by the Group and will allow jewellery casting manufacturers to work in an environment free of respirable silica, which will remove a major health risk should end users not conscientiously wear the recommended breathing protection apparatus.
This new invention will allow the Group to address the jewellery investment casting manufacturing market in the USA as, until now, it has been corporately forbidden for any Goodwin group company to sell products containing respirable silica into the USA.
This new product will assist Goodwin's seven jewellery investments casting powder manufacturing companies to further extend their global market share in the jewellery investment casting powder market where their share already exceeds 50%. As the new silica free product is a premium product, not only in quality but also on safety considerations, it should allow for further improvement in gross margin and profits earned in the Goodwin Engineering Refractory division over the coming years.  
Enquiries:  Jenny Martin, Company Secretary                     +44 (0)1782 220332
2nd April 2019
LEI: 213800N4T1NMSJ57B322
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEAPLAEALNEEF